Summary of ReShape Lifesciences Inc. Special Meeting Company Overview - **Company**: ReShape Lifesciences Inc. (RSLS) - **Date of Meeting**: August 07, 2025 - **Key Participants**: Paul Hickey (CEO), Tom Stankovich (CFO), Brett Hansen (Legal Counsel), Christina Vico (Inspector of Elections) Core Proposals Discussed 1. **Proposal Two**: Approval for the sale of substantially all of ReShape's assets - This proposal was a key focus of the meeting and was presented for voting [2][5] 2. **Proposal Three**: Approval and adoption of proposed amendments to ReShape's certificate of incorporation in connection with the proposed merger with Viome Therapeutics - This proposal was also highlighted for stockholder voting [2][5] Voting Process - The meeting was reconvened to allow stockholders to vote on the two proposals after a prior adjournment on July 24, 2025 [2][3] - Stockholders were informed that they could vote via a web portal or had the option to change their votes if they had already submitted them [4] - A quorum was confirmed to be present for the conduct of business [3] Preliminary Results - Preliminary results indicated that both proposals were approved by the stockholders [6] - The final vote tally is to be reported in a Form 8-K to be filed with the SEC within four business days following the meeting [6] Additional Notes - The meeting was conducted in a structured manner with designated roles for the participants, ensuring a formal process for the voting and discussion of proposals [3] - The focus on asset sale and merger indicates a significant strategic shift for ReShape Lifesciences, which may impact its future operations and market positioning [2][5]

Core Viewpoint - Intel is exploring the sale of its "NEX" network and edge division [1] Group 1 - The decision to explore a sale indicates a strategic shift within Intel [1] - The potential sale could impact Intel's overall business structure and focus [1] - This move may reflect broader trends in the technology sector regarding network and edge computing [1]